Post by Roche

At Roche, we are constantly evolving our science to tackle the most complex challenges in healthcare. Today, we are thrilled to announce a new research collaboration with C4 Therapeutics, Inc. (C4T) to pioneer a next-generation modality: Degrader-Antibody Conjugates (DACs). This agreement marks the third chapter in a decade-long partnership built on trust and a shared scientific vision. Swipe through to hear from our leaders and partners on the scientific and strategic potential of this exciting new frontier for patients. You can find all details here 👉 https://spkl.io/6047A2fjT #Roche #Innovation #Oncology #TargetedProteinDegradation #Partnership #C4Therapeutics #DACs